By Fineline Cube 
The Category 1 innovative drug Iscartrelvir, jointly developed by Westlake University, Westlake Laboratory, and Westlake Pharmaceuticals, has received marketing approval from China’s National Medical Products Administration (NMPA) for the treatment of mild to moderate novel coronavirus infection (COVID-19) in adult patients.
Regulatory Milestone & Development Partnership
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Category 1 innovative drug |
| Product | Iscartrelvir (oral small-molecule 3CLpro inhibitor) |
| Indication | Treatment of mild-to-moderate COVID-19 in adults |
| Approval Date | July 29, 2026 |
| Development Consortium | Westlake University + Westlake Laboratory + Westlake Pharmaceuticals |
| Intellectual Property | Novel scaffold structure with global patent protection |
Drug Profile & Mechanism of Action
- Molecule: Small-molecule inhibitor of SARS-CoV-2 main protease 3CLpro
- Administration: Oral formulation for outpatient treatment
- Target: 3CLpro (3-chymotrypsin-like protease), essential for viral self-replication and assembly
- Mechanism: Competitively binds to substrate-binding pocket of 3CLpro → prevents cleavage of polyprotein precursor → blocks viral replication
- Structural Innovation: Features a novel scaffold structure distinct from other 3CLpro inhibitors in development
Clinical Evidence & Therapeutic Significance
Phase III clinical studies demonstrated that Iscartrelvir exhibits significant efficacy with good safety and tolerability in patients with mild-to-moderate COVID-19. The drug addresses a continued need for effective oral antiviral therapies as the pandemic transitions to an endemic phase, particularly for high-risk populations who may progress to severe disease.
3CLpro represents a highly conserved viral target across SARS-CoV-2 variants, suggesting Iscartrelvir may maintain efficacy against emerging strains that could potentially evade other therapeutic approaches. This conservation makes 3CLpro inhibitors particularly valuable in the evolving COVID-19 treatment landscape.
Market Impact & Strategic Positioning
- Addressable Population: Millions of annual mild-to-moderate COVID-19 cases in China requiring outpatient treatment
- Competitive Differentiation: Novel scaffold structure may offer improved resistance profile compared to existing 3CLpro inhibitors
- Academic-Industry Model: Successful demonstration of Westlake’s integrated research-to-commercialization ecosystem
- Global Potential: Strong foundation for international regulatory submissions based on robust Phase III data
- Public Health Impact: Adds to China’s arsenal of domestically-developed antiviral therapeutics for pandemic preparedness
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical outcomes, and commercial expectations for Iscartrelvir. Actual results may differ due to risks including market adoption, competitive dynamics, variant evolution, and international regulatory requirements.-Fineline Info & Tech